2022年7月11日 · LMS-04 was a multicentre, open-label, randomised, phase 3 superiority study comparing the efficacy of doxorubicin alone versus doxorubicin plus trabectedin followed by …

2024年9月4日 · Combination therapy with doxorubicin and trabectedin induction, followed by trabectedin maintenance, was associated with improved overall survival and progression-free …

Methods: LMS-04 was a randomised, multicentre, open-label, superiority phase 3 trial, which included patients from 20 centres of the French Sarcoma Group (anticancer centers or …

The LMS-04 trial compared, as 1st-line treatment for patients (pts) with met or unresectable LMS, up to 6 cycles (cy) of Dox (75 mg/m 2) (arm A) vs up to 6 cy of Dox (60 mg/m 2) + Trab (1.1 …

2022年8月1日 · LMS-04 was a multicentre, open-label, randomised, phase 3 superiority study comparing the efficacy of doxorubicin alone versus doxorubicin plus trabectedin followed by …

LMS-04 was a randomised, multicentre, open-label, superiority phase 3 trial, which included patients from 20 centres of the French Sarcoma Group (anticancer centers or hospitals with an …

LMS-04 研究中，多柔比星和曲贝替定的联合治疗的 PFS 获益数据（13.5个月 vs 7.4个月）令人惊艳。 缓解率的获益（38% vs 13%）提示了联合治疗在肉瘤患者新辅助治疗中的获益可能性。

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, …

In the LMS-04 study primary analysis (NCT02997358), the combination of dox + trab demonstrated a significant progression-free survival (PFS) benefit (12·2 months versus 6·2 …

2024年10月6日 · This trial, LMS04, aimed to refine the treatment strategy for patients with metastatic leiomyosarcoma (LMS), specifically targeting the uterine and soft tissue subtypes. …